These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1719639)

  • 1. Experimental and clinical pharmacology of pentosan polysulfate.
    Maffrand JP; Herbert JM; Bernat A; Defreyn G; Delebassee D; Savi P; Pinot JJ; Sampol J
    Semin Thromb Hemost; 1991; 17 Suppl 2():186-98. PubMed ID: 1719639
    [No Abstract]   [Full Text] [Related]  

  • 2. Antithrombin and heparin cofactor II-mediated inactivation of alpha-thrombin by a synthetic, sulfated mannogalactan.
    Gracher AH; Cipriani TR; Carbonero ER; Gorin PA; Iacomini M
    Thromb Res; 2010 Sep; 126(3):e180-7. PubMed ID: 20553946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.
    Baba M; Nakajima M; Schols D; Pauwels R; Balzarini J; De Clercq E
    Antiviral Res; 1988 Sep; 9(6):335-43. PubMed ID: 2465736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacology of a heparinoid derived from pentosan].
    Lansen J; Diner H
    Agressologie; 1983 Dec; 24(12):591-5. PubMed ID: 6199994
    [No Abstract]   [Full Text] [Related]  

  • 6. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profibrinolytic and anticoagulant properties of the pentosan polysulphate derivative bego 0391.
    Klöcking HP; Hauptmann J; Richter M
    Pharmazie; 1991 Jul; 46(7):543-4. PubMed ID: 1723804
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithrombotic therapy in patients with known risk factors for thromboembolism.
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):927-34. PubMed ID: 2483712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR; Nazareth RA; Mourão PA
    Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prenatal pharmacology of low molecular weight heparin and pentosan polysulfate].
    Rainaut M; Forestier F; Daffos F; Fisher AM; Aiach M
    J Mal Vasc; 1987; 12 Suppl B():119-22. PubMed ID: 2452225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pentosan polysulfate on fibrinolysis: basic tests and clinical application.
    Vinazzer H
    Semin Thromb Hemost; 1991 Oct; 17(4):375-8. PubMed ID: 1725065
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
    Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
    Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate.
    Sié P; Fernandez F; Caranobe C; Gabaig AM; Boneu B
    Thromb Res; 1984 Jul; 35(2):231-6. PubMed ID: 6206589
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical studies on the fibrinolytic action of pentosan polysulfate].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):272-7. PubMed ID: 2427410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 18. Heparin-induced thrombocytopenia and pentosan polysulfate: treatment with a low molecular weight heparin despite in vitro platelet aggregation.
    Vitoux JF; Roncato M; Hourdebaigt P; Aiach M; Fiessinger JN
    Thromb Haemost; 1986 Apr; 55(2):294-5. PubMed ID: 2424119
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulphate in the thoroughbred horse.
    Orme CE; Harris RC
    Acta Physiol Scand; 1997 Feb; 159(2):179-85. PubMed ID: 9055947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.